has been shown to block ectopic discharges in axotomized sensory fibers and, thereby, may be of great interest for modulating some peripheral or central neuropathic pain symptoms. [15] ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

秋风送爽，丹桂飘香。近日（9月19日-22日），由中华医学会、中华医学会神经病学分会主办，河南省医学会承办的“中华医学会第二十七次神经病学学术会议”在美丽的郑州顺利召开。国内外知名专家学者齐聚，共享学术饕餮盛宴。神经病理性疼痛（NP）指由躯体感觉系统 ...

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition. The new findings could be especially ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

“The formation of Dogwood Therapeutics last month represents a transformational expansion of our pipeline with the addition of Halneuron ®, a non-opioid, novel NaV 1.7 modulator to treat neuropathic ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...